BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (URGP.OB), a specialty pharmaceutical company focused on the development of treatments for urological disorders, has initiated a double-blind, placebo controlled, cross-over study to investigate URG-101 as a treatment for acute symptoms of painful bladder syndrome/interstitial cystitis (PBS).
